Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma

International Journal of Cancer

Volumn 123, Issue 5, 2008, Pages 1215-1218

  Voelter, Verena ^a   Diserens, Annie Claire ^b   Moulin, Alexandre ^c   Nagel, Georg ^d   Yan, Pu ^a   Migliavacca, Eugenia ^e,f   Rimoldi, Donata ^c   Hamou, Marie France ^b   Kaina, Bernd ^d   Leyvraz, Serge ^a   Hegi, Monika E ^a,b,f  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^f National Center of Competence in Research in Molecular Oncology   (Switzerland)

Author keywords

Fotemustine; Liver metastases; MGMT gene silencing; Uveal melanoma

Indexed keywords

ALKYLATING AGENT; FOTEMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; EPIGENETICS; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LOW DRUG DOSE; MGMT GENE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GENE; UVEA MELANOMA; GENETICS; LIVER TUMOR; MELANOMA; METASTASIS; PATHOLOGY; PREDICTION AND FORECASTING; PROTEIN MICROARRAY; UVEA TUMOR;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MELANOMA; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UVEAL NEOPLASMS;

EID: 47249118393     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23632     Document Type: Article

References (27)

1. Scotto J, Fraumeni JF, Jr, Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976;56:489-91.
2. Hakulinen T, Teppo L, Saxen E. Cancer of the eye, a review of trends and differentials. World Health Stat Q 1978;31:143-58.
3. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992;110:245-50.
4. Desjardins L, Dorval T, Lévy C, Cojean I, Schlienger P, Slamon R, Validire P, Asselain B. Etude randomisée de chimiothérapie adjuvante par le Déticène dans le mélanome choroïdien. Ophtalmologie 1998;12:168-73.
5. COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119:670-6.
6. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589-95.
7. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006;17:578-83.
8. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
9. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000;60:5815-24.
10. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
12. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
13. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006;126:422-31.
14. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
15. Hoon DS. Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma? Nat Clin Pract Oncol 2004;1:74-5.
16. Kohonen-Corish MR, Cooper WA, Saab J, Thompson JF, Trent RJ, Millward MJ. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 2006;126:167-71.
17. Rastetter M, Schagdarsurengin U, Lahtz C, Fiedler E, Marsch W, Dammann R, Helmbold P. Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 2007;22:1005-15.
18. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
19. Wiewrodt D, Nagel G, Dreimüller N, Hundsberger T, Perneczky A, Kaina B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer 2008;122:1391-9.
20. Isowa G, Ishizaki K, Sadamoto T, Tanaka K, Yamaoka Y, Ozawa K, Ikenaga M. O6-methylguanine-DNA methyltransferase activity in human liver tumors. Carcinogenesis 1991;12:1313-7.
21. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665-70.
22. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000;88:469-73.
23. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001;7:2309-17.
24. Fornace AJ, Jr, Papathanasiou MA, Hollander MC, Yarosh DB. Expression of the O6-methylguanine-DNA methyltransferase gene MGMT in MER+ and MER- human tumor cells. Cancer Res 1990;50:7908-11.
25. Citron M, Graver M, Schoenhaus M, Chen S, Decker R, Kleynerman L, Kahn LB, White A, Fornace AJ, Jr, Yarosh D. Detection of messenger RNA from O6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 1992;84:337-40.
26. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, James CD, Passe S, Slezak J, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 2008;16:59-65.
27. Preusser M, Janzer R, Felsberg J, Reifenberger G, Hamou M-F, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner J, Hegi M. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 10.1111/j.1750-3639.2008.00153.x.